Linked Life Data

2082485

Source:http://linkedlifedata.com/resource/pubmed/id/2082485

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1991-5-9
pubmed:abstractText
The preventive effect of 300 mg/day dipyridamole, plus warfarin, on the development of thromboembolism after cardiac valve replacement was evaluated. Study 1 involved 71 patients receiving dipyridamole, 100 mg t.i.d., plus warfarin and resulted in a 2.8% incidence of thromboembolism. Study 2 involved 179 patients and compared the effectiveness of slow release capsules with tablet form dipyridamole at the same dosage, both plus warfarin. No thromboembolic episodes occurred in either group. No serious side-effects of dipyridamole were seen in either study. The results suggest that both slow release and tablet form dipyridamole in combination with warfarin are useful in the postoperative management of heart valve replacement.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0049-3848
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
27-33
pubmed:dateRevised
2008-2-28
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Dipyridamole combined with anticoagulant in prevention of early postoperative thromboembolism after cardiac valve replacement.
pubmed:affiliation
Department of Cardiovascular Surgery, National Cardiovascular Center, Suita, Japan.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial